Shingrix In Recipients of Allogeneic Transplants
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.
Allo-SCT recipients being age 18 - 79 years at time of allo-SCT. [+7]
Active Graft Versus Host Disease (aGVHD) at the time of enrollment and receipt o... [+7]